Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04246879
Recruitment Status : Recruiting
First Posted : January 29, 2020
Last Update Posted : September 16, 2021
Sponsor:
Information provided by (Responsible Party):
Duke University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to test whether an additional magnetic resonance image (MRI) sequence can improve the ability to distinguish radiation damage from tumor recurrence in participants with brain metastasis who have previously been treated with stereotactic radiosurgery (SRS).

Condition or disease Intervention/treatment Phase
Brain Metastases Other: MRI Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 37 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Diagnostic Accuracy of Delayed MRI Contrast Enhancement Characteristics and Radiation Necrosis Following Stereotactic Radiosurgery (SRS) for Brain Metastases
Actual Study Start Date : October 6, 2020
Estimated Primary Completion Date : October 2023
Estimated Study Completion Date : October 2023
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: MRI Other: MRI
Subjects undergo one additional delayed MRI sequence


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. number of positive MRI sequences along with positive tumor biopsies [ Time Frame: baseline ]
    true tumor will be detected by delayed MRI as determined by biopsy

  2. number of negative MRI sequences along with negative tumor biopsies [ Time Frame: baseline ]
    absence of tumor will be detected by delayed MRI as determined by biopsy


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients, age ≥18
  • Metastatic malignancy with at least 1 brain metastasis previously treated with SRS
  • Patients may have also received whole brain radiation therapy (WBRT) for management of brain metastatic disease but this is not required for study participation
  • Patients must have been diagnosed with a metastatic solid tumor of any histological type except small cell lung cancer (SCLC), or lymphoma.
  • Radiographic progression on post-SRS imaging at previously treated SRS site(s)
  • Must be a candidate for LITT procedure as determined by treating neurosurgeon and/or anesthesia team
  • Patients must sign study-specific informed consent prior to study entry

Exclusion Criteria:

  • Poor surgical candidate as determined by treating neurosurgeon and/or anesthesia team
  • Unable to undergo contrasted MRI (e.g. incompatible medical device, inadequate renal function per standard institutional clinical protocol, contrast allergy)
  • Small cell lung cancer (SCLC) or lymphoma histology
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04246879


Contacts
Layout table for location contacts
Contact: Joan Cahill, BNS RN OCN CCRP 919 668 5211 joan.cahill@duke.edu

Locations
Layout table for location information
United States, North Carolina
Duke University Health System Recruiting
Durham, North Carolina, United States, 27710
Contact: Eileen Duffy, BNS OCN CCRP    919-668-3726      
Principal Investigator: Scott Floyd, MD PhD         
Sponsors and Collaborators
Duke University
Investigators
Layout table for investigator information
Principal Investigator: Scott Floyd, M.D. Ph.D. Duke Health
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT04246879    
Other Study ID Numbers: Pro00103163
First Posted: January 29, 2020    Key Record Dates
Last Update Posted: September 16, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Duke University:
Laser Interstitial Thermal Therapy (LITT)
Stereotactic radiosurgery (SRS)
Magnetic resonance image (MRI)
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Brain Neoplasms
Neoplastic Processes
Neoplasms
Pathologic Processes
Central Nervous System Neoplasms
 Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases